Short Description BioViva CEO self‑experimenting with gene therapy.
Description Liz Parrish underwent telomerase and myostatin‑inhibitor gene therapy in 2015, sparking global debate on medical tourism and regulation. BioViva now works with CROs on multi‑country somatic gene‑therapy trials targeting aging syndromes. Parrish advocates compassionate‑use pathways and open biomarker reporting.